Fast Five Quiz: HER2+ Metastatic Breast Cancer Management

Winston Tan, MD


January 10, 2022

Breast cancer is the most frequently diagnosed life-threatening cancer in women. Despite significant advances in the treatment of early breast cancer, 30% of women go on to develop metastatic disease and recurrence. Approximately 20% of breast cancers are human epidermal growth factor receptor 2 positive (HER2+), which correlates with a more aggressive phenotype that metastasizes rapidly and recurs frequently.

While resection and adjuvant radiation may occasionally be an option to treat metastases in certain sites, in general, HER2 + metastatic breast cancer must be approached systemically so that treatment may reach all disease sites. Management of HER2+ metastatic disease requires careful sequencing considerations to help maximize overall survival while minimizing toxicity and adverse reactions.

Test your knowledge of HER2+ metastatic breast cancer management with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.